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 | Preface
Although preventable and curable, hepatitis C virus (HCV) infection is highly prevalent 
among people who inject drugs in Europe. The elimination of hepatitis C as a public health 
threat by 2030 is a target under Sustainable Development Goal 3 (SDG 3) on health, to 
which all EU countries have signed up. To achieve this target in the EU, it is crucial for 
services to reach people who currently inject drugs and who have done so in the past. This 
key population has a high disease burden and their access to HCV testing and treatment, 
as well as to other effective interventions that prevent and reduce the transmission of the 
virus, needs to be increased.
The importance of addressing the needs of people who inject drugs as part of action to 
achieve the elimination of hepatitis C cannot be overstated. Most studies in Europe find 
HCV antibody prevalence levels among this group of over 50 %, while surveys among 
people entering drug treatment show low rates of testing. Many barriers may prevent 
people who inject drugs from being tested for HCV, resulting in a reduced likelihood of 
them accessing treatment. Testing services are still mostly located in tertiary clinical 
settings, such as hospitals or specialist clinics, and thus may remain ‘out of reach’ 
for people who inject drugs. On the other hand, providers of harm reduction and drug 
treatment services are in close, often daily, contact with a large number of people who use 
drugs and could play a pivotal role in bringing HCV screening closer to this population, but 
often lack adequate training, equipment and resources.
This document has been produced as part of a wider initiative that the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is undertaking to support 
countries in the prevention and control of infectious diseases among people who inject 
drugs. It provides a step-by-step guide for those involved in planning and managing 
infectious diseases and drug services, focusing on how to identify barriers to and 
opportunities for improving provision of HCV testing and access to treatment for people 
who use drugs. In particular, it focuses on HCV testing in harm reduction and drug 
treatment settings. Based on work conducted by the EMCDDA, consultation with European 
partner organisations and pilots conducted in Luxembourg and Poland, it incorporates 
practical guidance on how to conduct a diagnostic process. It includes tools for assessing 
the need for and scale of HCV-related prevention responses and for ascertaining whether 
or not system-, provider- and client-level barriers to HCV testing exist. Importantly, this 
process has been undertaken with the full participation of all key stakeholders, allowing 
joint solutions to be developed and relevant actions to be planned together.
The piloting of the diagnostic process has demonstrated what can be achieved through 
working in partnership on this issue and we hope that this report will enable others to 
follow suit and, as a result, make good progress towards achieving the elimination of 
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 | Hepatitis C is widespread among people who inject drugs
Hepatitis C is a liver disease, which is caused by the hepatitis C virus (HCV), a blood-borne 
virus that is widely prevalent globally. In 60-85 % of those infected, hepatitis C becomes 
a long-term chronic disease, which can have fatal consequences due to the development 
of liver cirrhosis and hepatocellular carcinoma (Hofstraat et al., 2017). People who inject 
drugs remain a key group at risk of HCV infection in most European countries, as a result 
of insufficient awareness and widespread unsafe injection practices such sharing injection 
equipment. Available national estimates of antibody prevalence among this group suggest 
that more than one out of two people who inject drugs in Europe may have been in contact 
with HCV (EMCDDA, 2020). Transmission through injecting drug use is ongoing and 
accounts for a substantial proportion of newly reported HCV infections where transmission 
mode is known (ECDC, 2019).
Safe and highly effective treatment in the form of direct-acting antiviral (DAA) regimens 
for hepatitis C is now available. This progress has prompted many European countries 
to adopt new viral hepatitis strategies and update guidelines to broaden access to HCV 
testing and treatment. The reduction in the price of direct-acting antiviral medicines 
has enabled treatment to be rolled out rapidly in a number of European countries. The 
challenges that remain are low levels of HCV testing and unclear referral and treatment 
pathways, both of which pose particular barriers for people who inject drugs.
 | The elimination of hepatitis C as a global policy goal
Health features prominently in the 2030 Agenda for Sustainable Development and one 
of its 17 global Sustainable Development Goals (SDGs) is to ‘ensure healthy lives and 
promote wellbeing for all at all ages’ (1). Within this goal, a specific target on health 
addresses HIV, hepatitis and tuberculosis as globally relevant communicable diseases:
‘By 2030, end the epidemics of AIDS, tuberculosis, malaria and 
neglected tropical diseases and combat hepatitis, water-borne 
diseases and other communicable diseases’ (2).
To accelerate progress towards the health-related SDGs, close cooperation between 
health, development and humanitarian agencies at the global level has been established 
(WHO, 2019).
(1)  UN Sustainable Development Goals website: https://www.un.org/sustainabledevelopment/health/
(2) Ibid
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The EU is fully committed to being a frontrunner in implementing the 2030 Agenda for 
Sustainable Development, together with its Member States. Several EU ‘initiatives on 
health and the EU Cohesion Policy support and complement national governments in 
their efforts to improve and protect human health, to reduce inequalities in health status 
and promote social inclusion. The European pillar of social rights underlines the right of 
every individual to timely access to affordable, preventive and curative health care, long 
term care and good quality essential services. It also covers social protection, including 
healthcare and sickness benefits’ (European Commission, 2020).
To incorporate the health target into a global operational policy framework for hepatitis, 
the World Health Assembly endorsed in May 2016 the global health sector strategy on 
viral hepatitis, which aims to eliminate hepatitis as a public health threat by reducing the 
incidence of chronic infections by 90 % and mortality by 65 % by 2030 (WHO, 2016a). 
To support the implementation and monitoring of this strategy, a framework with 10 core 
indicators has been proposed by the World Health Organization (WHO). These include 
a mix of epidemiological and programmatic indicators (WHO, 2016b). This framework also 
stresses the importance of including comprehensive harm reduction services for people 
who inject drugs in the strategy (see box).
Testing and linkage to treatment is a core component of a hepatitis C elimination 
strategy, because of both the direct benefits of treatment for the infected individual and 
the indirect impact of treatment on reducing transmission in the community. Achieving 
elimination among people who inject drugs will require a significant scale-up of prevention 
interventions within drug services, including increased testing (see box). In line with the 
EU’s commitment to achieving the SDGs, the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) and the European Centre for Disease Prevention and Control 
(ECDC) collaborate closely with the WHO to support EU countries in their elimination 
efforts through monitoring, public health guidance and best practice dissemination 
(Duffell et al., 2017; EMCDDA, 2019a). The work of the EMCDDA is focused on people 
Harm reduction as part of a comprehensive response
‘A package of harm reduction services for PWID [people who inject drugs] can be 
highly effective in preventing transmission and acquisition of viral hepatitis A, B and C, 
as well as HIV and other blood borne infections. Such a package should be integrated 
into a comprehensive set of services for the prevention and management of substance 
use disorders.’ (WHO, 2016a, p. 21).
The comprehensive package consists of the following interventions:
1. needle and syringe programmes
2. opioid substitution therapy and other drug dependency treatments
3. HIV testing and counselling
4. antiretroviral therapy
5. prevention and treatment of sexually transmitted infections
6. condom programmes for people who inject drugs and their sexual partners
7. targeted information, education and communication
8. prevention, vaccination, diagnosis and treatment of viral hepatitis
9. prevention, diagnosis and treatment of tuberculosis.
For more information see: https://apps.who.int/iris/bitstream/hand
le/10665/246200/9789241511124-eng.pdf?sequence=8
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who inject drugs, one of the population groups that are particularly vulnerable to hepatitis 
C and frequently lack adequate access to services. Following the WHO framework of 
indicators, the agency monitors developments in national policies that target this group, 
the epidemiological trends in regard to hepatitis B and C, as well as the level of access to 
core harm reduction measures such as the provision of clean drug injection equipment 
and drug treatment (EMCDDA, 2019b).
 |  Drug services as priority settings for hepatitis C virus testing
Testing is the gateway to accessing treatment and, to achieve HCV elimination, particular 
efforts are needed to reach those at risk and undiagnosed. Because people infected with 
HCV often do not have any symptoms, people who inject drugs infected with HCV may 
be unaware of their infection. The importance of testing, early diagnosis and treatment of 
all people who are chronically infected is highlighted in current international guidelines 
(EASL, 2018; WHO, 2018).
The latest European testing guidance (ECDC, 2018) stresses the importance of a stronger 
focus on people who inject drugs and other groups most at risk, to interrupt viral hepatitis 
transmission chains and prevent further infections.
‘In order to interrupt existing transmission chains and prevent further 
infections, Europe needs a stronger focus on working closer with 
vulnerable populations to help better detect those with undiagnosed 
infections, then link them to appropriate health care services. 
Increasing testing coverage and uptake, especially for those most at-
risk, is an essential element of any strategy to eliminate HBV [hepatitis 
B virus], HCV and HIV in the European Union and European Economic 
Area (EU/EEA)’ (ECDC, 2018, p.1).
The past decade has seen important biomedical advances that have made a significant 
contribution to promoting the early diagnosis of HIV and viral hepatitis, and new 
medications have significantly enhanced the effectiveness of treatment of chronic 
hepatitis. New testing technology is available that makes testing outside specialist settings 
easy, and new direct-acting antiviral treatments for hepatitis C, which cure the disease 
within 12 weeks with fewer side effects than previous treatment options, are available.
Bringing health services to those who have a particular need for them is part of ensuring 
a people-centred approach to health (EMCDDA, 2017), and these technological 
developments provide an opportunity for new models of care to be developed that provide 
a more adequate and timely response for hard-to-reach groups, such as people who inject 
drugs. However, taking advantage of these opportunities may need a reorientation of 
service provision and a range of barriers may exist that need to be addressed to enable 
successful implementation.
The diagnostic process described in this document provides a way of identifying barriers 
to and opportunities for improving the provision of HCV testing and care for people who 
use drugs and, at the same time, making progress towards meeting the HCV elimination 
targets.
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 | Introducing the diagnostic process
As highlighted in the previous section, people who inject drugs are at particularly high risk 
of HCV infection but tend to have low rates of access to testing and treatment in Europe. 
The diagnostic process for identifying barriers to and opportunities for improving HCV 
testing and referral to care for people who inject drugs described in this document brings 
together a variety of stakeholders to identify problems and areas for improvement.
The main mechanism and core activity of the diagnostic process for identifying barriers 
to HCV testing in drug services (the ‘problem’) is to use a participatory dialogue between 
stakeholders as a basis for identifying actions to improve the situation (‘solving’ the 
problem).
While the focus and the objectives of the diagnostic process, as well as which participants 
should be invited to take part, will differ according to the needs and situation in 
a given national or local context, the process and steps to consider while planning the 
implementation of the diagnostic process are similar. This document discusses the key 
issues to be considered, regardless of the country and context-specific situation.
The diagnostic process consists of three main steps (see Figure 1).
The starting point for the diagnostic process is the mapping of information on the current 
situation, including the assessment of the need for HCV testing in drug services. This may 
include in particular an assessment of available data on the prevalence of HCV antibodies 
among people who inject drugs and of acute and chronic HCV infections. Common risk 
behaviours and prevention coverage should also be assessed, as well as national or local 
testing policies for this key population. It will be important to map the infrastructure of 
testing currently available to people who inject drugs, including opportunities for HCV 
testing in drug services. A checklist (see Figure 3 and Appendix 1) should then be used 
to identify system-, provider- and client-level barriers to testing in drug services. This is 
discussed in more detail in the section on Step 1 below.
Ensuring 
monitoring
and evaluation1 2 3Multi-stakeholderconsultation toidentify barriers
and solutions
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Introducing the diagnostic process
The core element of the process is a multi-stakeholder round-table meeting (Step 2), 
bringing together representatives from:
 ■ the system level, such as policymakers and service planners;
 ■ the provider level, that is, providers of infectious disease and drug 
services;
 ■ the client level, to ensure that the experiences of people who use drugs 
are also taken into account.
The aim of this meeting is to identify the barriers to HCV testing and treatment for 
people who inject drugs, to clarify the key target areas for improvement of HCV testing in 
drug services and to identify priority actions to address the most important issues (see 
EMCDDA guide to holding a stakeholder round table on supporting HCV testing and care 
in drug services).
The final element of the diagnostic process (Step 3) is dedicated to ensuring monitoring 
and the evaluation of outcomes. It typically involves preparing a report on the stakeholder 
meeting, linking the activities aimed at removing barriers to HCV testing for people who 
inject drugs that were proposed by stakeholders to local or national policies, such as the 
hepatitis elimination strategy, and defining the expected results of implementation, ideally 
linked to pre-defined indicators.
Importantly, the diagnostic process can be flexible and tailored to national or local needs 
and situations. In many cases, it will not be possible to get all relevant stakeholders 
together at one time, or to consider barriers to community-based testing and care at all 
levels (3), because of missing information. However, a start can be made and areas for 
action to improve the situation can be identified. It can be useful to repeat the diagnostic 
process or one or more of its steps to identify further issues to be addressed over time.
(3)  This manual covers the promotion of HCV testing and care in drug services in the community. It does not address HCV 
testing in prison settings, which requires a different approach.
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The EMCDDA tools available to support the mapping exercise are as follows:
 ■ EMCDDA elimination barometer
 ■ checklist of potential barriers to HCV testing among people who inject 
drugs (Appendix 1)
 ■ knowledge questionnaire on viral hepatitis for drug service staff.
The diagnostic process starts with a needs assessment exercise, aimed at mapping 
the situation and describing the context in which the stakeholder round table will take 
place. Understanding what is known about the extent and nature of the HCV problem 
is important background knowledge and contextual information for successfully 
implementing the stakeholder round table. Knowing the size of the key population, as 
well as the policies and available infrastructures for testing and linkage to hepatitis care 
in the country or region, will help in preparing the dialogue for the relevant stakeholders 
and selecting the target audience, and will help stakeholders to choose the appropriate 
objectives. However, if the available information is very limited, it may also be possible 
to collect some information directly from experts, either beforehand or during the 
introductory session at the stakeholder meeting.
 | The EMCDDA elimination barometer
The EMCDDA elimination barometer (EMCDDA, 2019b) was developed by the EMCDDA 
together with its expert network on drug-related infectious diseases as a follow-up to 
the first global health sector strategy on viral hepatitis, endorsed by the World Health 
Assembly in 2016. It reflects the global WHO indicators for monitoring progress towards 
the elimination of viral hepatitis, according to the global health sector strategy monitoring 
and evaluation framework, and includes 17 indicators relevant for the key population, 
people who inject drugs (Figure 2).
A first technical report published in September 2019 presents data from the EU countries, 
Norway, Turkey and the United Kingdom relating to the 2020 targets of the WHO’s 
regional action plan for viral hepatitis in the European region (EMCDDA, 2019b). Data 
sources include the EMCDDA’s national focal points and its European network of experts 
in the field of drug-related infectious diseases as well as published reports and studies. 
The indicators cover, among other things, the burden of HCV and HBV infection among 
people who inject drugs in each country; the level of coverage of selected prevention 
interventions, namely of opioid substitution treatment for those dependent on opioids; the 
level of coverage of clean injecting kits for those who inject drugs; and the availability of 
Assessing 





Step 1 I Assessing the need for hepatitis C testing in drug services
HBV vaccinations for people in prison. Furthermore, the percentage of people who inject 
drugs entering drug treatment services who report having been tested for HCV antibodies 
in the past 12 months is used to highlight potential missed opportunities for diagnosing 
HCV infection in people who inject drugs. Finally, national HCV policies and clinical 
guidelines are assessed to check if they include barriers among people who inject drugs to 
accessing direct-acting antiviral treatment.
The data compiled in the national ‘elimination barometer’ for a specific country provide 
a useful overview of the information that is routinely reported and also show the indicators 
for which data are lacking. It is also worthwhile gathering additional data and contextual 
information beyond the 17 indicators, for example data relating to the national drug 
treatment system, and on drug and infectious disease policies and regulations.
A collection of other potentially valuable sources of information can be found in the 
resources section of the web page dedicated to the EMCDDA initiative on increasing 
access to hepatitis C care through drug services. In addition, there may be local and 
national studies, both published and unpublished, that have some information that helps 
to provide a picture of both the need for HCV testing and the current provision.
It is useful to collaborate with researchers in the field to prepare an overview of the current 
situation, as this can provide an opportunity to share the latest findings from relevant 
research. The round-table meeting will also offer an opportunity for the stakeholders 
invited to present additional formal and informal data, including activity reports from local 
Note: DAA = direct-acting antiviral













Prevalence of HCV and HBV
Hepatitis national policy/action plan inclusive of PWID
Sterile needles/syringes distribution
Opioid substitution treatment coverage
HBV vaccination ability in prison
HCV/HBV testing availability in drug facilities/prisons
Proportion of PWID tested for HCV in the last year
Notications of acute and chronic HCV/HBV cases
DAA treatment availability for PWID
Prevalence of HCV among young and new PWID 
(proxy for incidence)
Indicators available and 
context documented
National policy adopted
200 per PWID per year
40 % in treatment
HBV vaccination available
50 % of PWID with chronic
HCV/HBV diagnosed
75 % of eligible patients treated
30 % reduction (baseline = 2015)
























Indicators and targets in the EMCDDA hepatitis elimination barometer
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service providers, or reports about the clinical management of patients or the cascade of 
care for hepatitis (4).
The overview of the situation should be as comprehensive as possible, but a lack of 
certain data should not be seen as a barrier to progress in the diagnostic process or to the 
organisation of a stakeholder meeting. Information gaps can be an important element for 
discussion and may be one of the barriers to improving provision.
 |  The checklist of potential barriers to hepatitis C testing among people who inject drugs
A second core input for the diagnostic process is a checklist of potential system-, provider-, 
and client-level barriers to HCV testing (see Appendix 1) (Sperle-Heupel et al., 2018). 
The checklist is based on the available literature and expert knowledge, and structured 
into three parts, one for each type of barrier: system-level, provider-level and client-level 
barriers. Barriers are then organised into sub-categories within each of the three levels 
(see Figure 3 and Appendix 1). The checklist is a useful tool for organising and focusing 
the discussions at the stakeholder meeting, and the barriers listed can also be the basis 
for statements or questions that may be used in preparation for the meeting, as part of 
a survey, or at the meeting itself in plenary sessions or workshops to stimulate discussions. 
However, it is important to note that the checklist topics are by no means exhaustive 
and it is advisable to ensure that the discussion is facilitated in a way that allows the 
identification of additional barriers that may be of particular importance in the country 
and/or settings under discussion but that may be missing from the EMCDDA checklist.
The checklist is therefore a very flexible tool (see the scenarios in the accompanying 
EMCDDA Guide to holding a stakeholder round table on supporting hepatitis C testing 
and care in drug services). Depending on circumstances, an online version of the checklist 
may be preferred, using an online survey tool such as EU Survey, or the survey could 
simply be printed and distributed. The checklist questions can be answered individually 
or as a group. Sending the checklist out before the stakeholder meeting may allow the 
consultation to involve a larger number of people than could be accommodated at the 
event itself, with the results being brought together for discussion at the meeting. Having 
an anonymous online version may be useful if there are concerns that some groups, for 
example service staff or people who inject drugs, may not feel comfortable speaking 
openly at a large group meeting.
(4)  A cascade of care for hepatitis is commonly determined by the number of patients with chronic HCV infection, the 
number of patients diagnosed with chronic HCV infection, the number of patients linked to HCV care, the number 
of patients being treated with antiviral medication for HCV infection and the number of patients with a sustained 
virological response.
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FIGURE 3
Checklist at a glance
Note: For more information, see full checklist in Appendix 1.
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 |  Knowledge questionnaire on viral hepatitis for drug service staff
The EMCDDA published a knowledge questionnaire as part of its initiative to increase 
access to hepatitis C care through drug services. The main aims of the knowledge 
questionnaire are to refresh knowledge on HCV and HBV transmission, testing and care for 
people who inject drugs among those working in drug treatment settings, and to increase 
awareness among staff of the importance of knowing their own status.
The knowledge questionnaire covers a wide range of aspects regarding viral hepatitis 
B and C, such as prevalence, routes of transmission, prevention measures, treatment and 
testing options, and international recommendations on testing and treatment.
The literature shows that knowledge about new hepatitis treatment and testing methods 
among staff working in harm reduction settings is not always sufficient or up to date. 
This may have implications for the clients, who may not be informed by staff about 
new developments in this area and, as a result, may be less willing to be tested and/or 
treated. Therefore, in the context of the diagnostic process, the knowledge questionnaire 
can be used to identify existing barriers at the level of service providers. The knowledge 
questionnaire can be implemented at the beginning of the diagnostic process in selected 
drug treatment services, and the results of the exercise can inform discussions at the 
stakeholder meeting when system-level barriers and opportunities are considered. If 
the level of knowledge is low, the information collected and documented could lead to 
the inclusion of a training provision for staff of drug treatment centres in the document 
summarising outcomes or in an action plan. If the situation is the opposite, and staff are 
well informed about recent developments in HCV treatment and testing for people who 
inject drugs, any investment can go into other areas of work. Moreover, at a later stage, 
the information collected through the knowledge questionnaire can serve as a basis for 
monitoring and evaluation (see also Step 3 below).
15 
The EMCDDA tools available to support the stakeholder round table are as follows:
 ■ a guide to holding a stakeholder round table, including:
 » a draft agenda of the meeting
 » case study examples of conducting a stakeholder meeting in two EU Member 
States
 » an example of a meeting evaluation questionnaire.
The core element of the diagnostic process is a structured round-table discussion. This 
format is well suited to the purpose of bringing together different groups of stakeholders, 
with different perspectives, backgrounds and knowledge. The participatory approach 
aims to foster a better understanding of the current situation and needs in regard to the 
HCV testing of people who inject drugs at the national or sub-national level, and to help 
stakeholders to identify opportunities and make concrete and realistic plans for actions 
that will promote HCV testing and access to care for people who inject drugs.
There are three main stages to organising a stakeholder event that need to be considered.
The first stage is related to planning and preparation for the stakeholder meeting, which 
involves key elements such as establishing a core team composed, at a minimum, of 
a drug specialist and an infectious disease expert, and formulating the objectives of the 
meeting. The latter should be supported by the review of the needs assessment for HCV 
testing and care in drug services (carried out in Step 1 of the diagnostic process), and 
consideration of what can realistically be achieved within the time frame and at a single 
stakeholder meeting. Identifying a small number of priority objectives that should be 
addressed at the meeting and selecting which level of government (local, regional, national 
or a combination) will impact on the implementation of change will help to determine 
which partners should be invited to the meeting, that is, which partners are most suited 
to addressing the topics in question successfully and covering areas outside the areas of 
expertise of the core team.
The first stage can be quite time consuming, as it also involves a needs assessment 
exercise, consultations with experts, agreeing on the date and place of the meeting, 
and selecting the facilitator and presenters. There is no single mix of people best suited 
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the objectives of the event and the available resources. Yet, it is crucial to ensure that 
there is representation from all three levels (system, provider and client; see Figure 4), 
with participants with appropriate competences in decision-making, sound technical 
knowledge and a client perspective.
The second stage is related to holding the stakeholder round-table meeting. The length 
and the structure will be determined by the objectives of the meeting and the availability 
of the experts. However, a minimum of half a day should be set aside to address the 
topic. Preparatory work, including the collection of information ahead of the meeting, 
may facilitate the organisation of the day. It can be useful to start meetings with a brief 
illustration of the situation based of the needs assessment exercise (Step 1 of the 
diagnostic process), to ensure that participants have a common understanding of the 
situation and the baseline. The format selected is a round table, a technique that allows 
the building of consensus and seeking of solutions among formal decision-makers 
and representatives from other sectors of society. By definition, it is a closed meeting 
that should aim to confront issues rather than people and create a win-win situation 
for all participants. There is a lot of flexibility for meeting organisation, as shown by the 
three different scenarios provided in Appendix 2 and in the EMCDDA Guide on holding 
a stakeholder round table on supporting HCV testing and care in drug services. These 
scenarios are based on the experience of several EU Member States that have already 
organised their first consultations in line with the EMCDDA guidance. All the scenarios 
include an important session where solutions, including existing good practices, are 
discussed. This session could potentially be scaled up or replicated.
The third and final stage of the stakeholder round-table meeting is dedicated to ensuring 
that the meeting produces useful outputs. This can to some extent be done during a review 
session at the meeting, but it may be helpful to agree with the meeting participants on 
a follow-up process in which they formally agree on and sign up to contributing to a report 
on the meeting. The meeting report, including — if applicable — any actions and indicators 
agreed on, will later provide valuable input to Step 3 of the diagnostic process, which is 




Treatment fund/insurance fund representatives
Sta involved in diagnostic testing
Sta from hospital/clinic settings (link to care)
Drug treatment and harm reduction sta
Community/advocacy group representatives
Prison physicians
Community/advocacy group representatives 
(for people who inject drugs or with HCV infection)
Clients in contact with harm reducton services
Community/advocacy group representatives


















Who to consider inviting to the stakeholder meeting to identify barriers and solutions 
to HCV testing and care among PWID in drug services
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The EMCDDA tools available to support monitoring and evaluation are as follows:
 ■ EMCDDA elimination barometer
 ■ knowledge questionnaire on viral hepatitis for drug service staff
The final step in the diagnostic process aims to ensure that the results of the stakeholder 
round table are followed up and that the implementation of any actions that the 
stakeholders at the meeting agreed on is monitored and that results are evaluated. The 
content of this step can vary, as it depends entirely on the objectives of the meeting. For 
example, if the objective was to simply get consensus on the main barriers to HCV testing 
for people who inject drugs in drug treatment services, then a report listing the barriers 
identified will suffice. However, if the objective of the meeting was to identify potential 
actions to overcome these barriers, then the development of an action plan might be the 
most appropriate outcome; an action plan might include plans on how to address potential 
information gaps.
If an action plan is developed, it will be important to be realistic about what can be 
achieved, as it may not be possible to address all barriers at once. It can be useful to 
structure action plans so that consideration is given in turn to actions that can be taken 
immediately — the ‘quick wins’ — which will often be small changes made by individual 
participants; medium-term actions, which can be achieved reasonably quickly; and longer- 
term actions, for example if legislative changes are needed.
To ensure that the diagnostic process, including the outcomes of the round-table 
discussion, have an impact and help to improve current practice, it is important to produce 
a report on the stakeholder meeting and ensure that it is disseminated widely.
Ideally, the meeting report will include a list of actions and the actors responsible for taking 
these actions, and indicators against which to measure progress. The indicators should 
link to the indicators in the EMCDDA elimination barometer, based on the global evaluation 
framework and comparable across all EU Member States (see Step 1). Table 1 shows an 
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TABLE 1
Suggested table with action points from the round-table discussion
Action point 
(what do 
















It is good practice to arrange a consultation process (online or face to face) to discuss 
and review the meeting report, and the actions, indicators and intended outcomes agreed 
on. This consultation should involve all stakeholder levels and serve as an opportunity to 
modify and improve the report, to ensure maximum impact through endorsement by all 
stakeholders.
Different tools can be used to monitor and evaluate progress, including the EMCDDA 
elimination barometer (see Step 1) and the knowledge questionnaire for staff working 
in drug services. These tools allow the assessment of changes in the epidemiological 
situation, in response measures and in HCV knowledge by comparing the results at the 
beginning of the diagnostic process with the situation at the end of the process.
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National regulatory framework Society level/ 
discrimination
Organisation of testing and 
treatment on national level
Epidemiological 
situation
No national policy 




policy in place 
for unrestricted 





Testing for HCV 
is not provided by 
OST services
Testing for HCV 
is not provided 
by other drug 
services
Lack of evaluation 
and monitoring 





Lack of HCV 




strategy in place 
for HCV testing of 
PWID
No public funding 
available for HCV 
screening
Medical doctor 




guidelines for HCV 
testing of PWID
Restriction to access 
to any services due to 
HCV status
Lack of HCV 
incidence data for 
PWID
National drug 
laws identified as 
a barrier
No public funding 
available for HCV 
treatment
HCV treatment 




HCV testing of 
PWID
Breach of 
confidentiality – (link 
to other systems, e.g. 
police registries)
Lack of data on 
HCV testing of 
PWID
Stigma
Fear of stigma if tested HCV 
positive
Negative experiences with 
health care or drug service 
staff/stigmatised when tested 
for HCV
Stigma/shame of using drugs
Competing problems
Other health problems (e.g. 
mental health problems)
Lack of housing
Lack of sufficient food









Insufficient knowledge of HCV
Insufficient knowledge of 
hepatitis C treatment options
Myths about HCV e.g. “I have 
no symptoms so I have no 
problem”
Fear that drawing blood will 
damage veins
Perception of HCV
Perceive risk of HCV as low 
and not as serious as HIV
Cultural attitudes towards 
infection/no need to avoid 
infection
Access
It takes too long time to get 
tested
The service is too far away 
(location)
The hours where you can get 
tested do not fit the schedule 
of the client
Language barrier
Lack of/poor available 
transportation to the service
HCV services restricted to 
those in addiction care (OST)
Two step testing (HCV 
serology and HCV RNA)
Consequences of a 
positive test result
No hepatitis C treatment 
available if tested positive
Fear of losing children  
(to child services)
Fear of negative impact on 
the asylum procedure (for 
migrants)
Fear of HCV testing/knowing 
results











Low level of knowledge of HCV among staff in harm 
reduction agencies 
Low level of knowledge of HCV among staff in drug 
treatment, including OST services
HCV testing is not perceived as the area of 
responsibility of the staff in drug services 
Scared of stigmatising client when asking about HCV
Assumption by staff: HCV testing is too complicated
HCV treatment not offered if current drug use
External barriers
Insufficient staff available to offer 
HCV testing services
High fluctuation of staff in drug 
services
Insufficient availability of 
information materials
Service not set up to support 
minority populations (e.g. lack 
of translated materials, no 
interpretation)
Lack of time to offer HCV testing Lack of referral pathways to HCV 
care and treatment
Lack of available funding to offer 
HCV testing services
Lack of available equipment to 
perform testing services
Point-of-care (POC) HCV testing 
not available in drug treatment 
services
No existing collaboration with 
laboratories for confirmatory HCV 
testing
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1.  Does my government have a 
national screening strategy in place 
for HCV testing of PWID?
2.  Does my government have a national 
policy in place for unrestricted 
access to HCV treatment? 
3.  Does this policy include treatment of 
HCV for active PWID?
4.  Is public funding available for HCV 
screening of PWID?
5.  Is public funding available for HCV 
treatment of PWID?
6.  Is the national drug policy having an 
impact on PWID’s access to HCV 
































1.  In my country and 
setting, is HCV 
testing permitted 
without a medical 
doctor?
2.  In my country, is 
testing for HCV 




3.  In my country, is 
testing for HCV 
provided by most 
drug services?









6.  Are there data on 
the prevalence of 
HCV for PWID?
7.  Is there political 





8.  Is there financial 





9.  Are there 
programmes 
implemented for 
HCV testing of 
PWID?  
10.  National HCV 
plan is followed 


















1.  In my country, stigma and 
discrimination against PWID are not 
a problem
2.  In my country, stigma and 
discrimination against people living 
with HCV are not a problem
3.  In my country, people diagnosed with 
HCV are restricted from accessing 
some types of services or functions 
















1.  Is HCV national action 
plan being monitored and 
evaluated?
2.  Is data on HCV prevalence 
among PWID available?
3.  Is data on HCV incidence 
among PWID available?
4.  Is data on HCV testing 
among PWID available?
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Appendix 1 I Checklist of barriers for HCV testing










1.  Is the level of knowledge 
of HCV among the staff 
working in drug treatment 
services known?
2.  Is the level of knowledge 
of HCV among the staff 
working in OST services 
known?
3.  Is knowledge of HCV 
among staff sufficient to 
address HCV with clients?
4.  Is HCV testing perceived 
as the responsibility of 
the staff in drug treatment 
services?
5.  HCV-related stigma is not an issue 
among staff in drug treatment 
services
6.  HCV testing is considered easy and 
straight forward among the staff in drug 
treatment services
7.  The staff in drug treatment 
services have other priorities 












1.  Is there sufficient staff to 
offer HCV testing in drug 
treatment services?
2.  Is the staff in drug 
treatment services 
sufficiently trained to offer 
and provide HCV testing?
3.  Is there sufficient funding 
to perform HCV testing 
services?
4.  Is equipment available to 
perform HCV testing in 
drug treatment services?
5.  Does a collaboration 
with laboratories exist 
for confirmatory HCV 
testing?
6.  Is POC testing available in 
drug treatment services?
7. Are drug treatment 
services sufficiently provided 
with information materials?
8.  Is there stability in the 
staff so that those trained 
in HCV testing services 
are there for a longer 
period of time?
9.  Is there sufficient time for 
staff in drug treatment 
services to offer testing?
10.  Are there sufficient 
supporting materials 
available for conducting 
counselling also in 
different languages?
11.  Do pathways exist for 
referral to HCV care?
12.  Is the staff in drug 
treatment services 
aware of the HCV care 
pathways and how to link 
people to care? 
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lt 1.  Is treatment available for those 
with hepatitis C? 
2.  Are clients assured that they will not lose 
their child if they are tested positive? 
3.  Are clients assured that they will 
not be deported if they are tested 
positive? 








1.  Are clients in drug 
treatment services well 
informed about the 
hepatitis C virus? 
2.  Cultural beliefs among 
clients prevent or delay 
HCV testing 
3.  Myths such as “my HCV is 
incapsulated” exist among 
clients
4.  Are clients in drug 
treatment services well 
informed about hepatitis 
C treatment?
5.  Is the idea that drawing blood 
‘harms their veins’ common 
among PWID?
6.  Do clients know that the risk of HCV 
infection is higher than HIV among clients 
in drug treatment services?
7.  Is HCV infection perceived as 






1.  It takes too long to get 
tested
2.  Testing services are not 
easy to reach 
3.  Opening hours of testing 
services do not fit clients’ 
needs.
4.  Language barriers exist.
5.  Transportation options to reach 
the service are insufficient.
6.  Hepatitis C treatment is restricted to 
those in addiction therapy (current PWID 
cannot access)













s 1.   Other health problems 
prevent PWID from 
getting the HCV test
2.  Lack of housing prevents 
PWID from getting the 
HCV test
3.  Lack of sufficient food 
prevents PWID from 
getting the HCV test
4.  Lack of personal financial 
resources prevents PWID 






1.  Fear of stigma if tested positive 
is an issue among clients in drug 
treatment services 
2.  Negative experiences with health care or 
drug treatment service personnel prevent 
clients in drug treatment services seeking 
health care?
3.  Stigma and shame related to 
using drugs is an issue in my 
country. 
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 | Appendix 2  Three round-table scenarios
 | Scenario 1
Description of the situation
There is a high prevalence of HCV among people who inject drugs in country X (60 %). 
There is no law that prohibits HCV testing from being implemented in drug services, and 
a national plan, which includes testing of people who inject drugs, has been in place 
since 2017. Data on people who inject drugs are difficult to collect from country X, but 
surveys suggest that HCV testing rates among people who inject drugs and the proportion 
diagnosed and linked to care are low. HCV testing is implemented in very few drug 
treatment services, and these services are located in or close to the country’s capital city. 
The reasons why few drug services have implemented HCV testing are unknown.
Objectives
The objectives are to identify the main barriers at the provider and client levels (the five 
most important barriers at each level) that hinder implementation of HCV testing, and to 
identify possible solutions to overcome each of the barriers identified.
Participants
 ■ Four representatives from the provider level: two from a drug service 
that implements HCV testing and two from a drug service that has not 
implemented HCV testing.
 ■ Four representatives from the client level: two who attend the drug 
service that offers HCV testing and two who do not attend and have not 
been tested for HCV.
Structure of the discussion and use of checklist
After a round of introductions and the presentation of basic ground rules and the 
objectives of the meeting and the agenda, the discussion could start with the 
consideration of provider-level barriers, by addressing, together with the participants, the 
questions related to the provider level in the checklist, for example:
 ■ Is knowledge of HCV among staff sufficient to address HCV among clients?
 ■ Is HCV testing perceived as the responsibility of the staff in drug 
treatment services?
The meeting facilitator could discuss the questions (choose a number that time will 
permit) with the participants. Once the facilitator has gone through the checklist and the 
questions, a list of barriers, in order of priority, could be made and the five most important 
at the provider level identified. Before starting the prioritisation, the barriers identified 
could be grouped according to level. For the prioritisation of barriers, participants could 
be asked to mark the most important barrier (e.g., with a red sticker) to see which of the 
barriers receive the most votes. Once this step is complete, possible solutions to overcome 
the most important barriers identified could be discussed. For this, it would be a good idea 
to draw on the experience of the participants from drug services that have already been 
successful in implementing HCV testing.
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The next step (which could be after a break) would be to identify the barriers at the client 
level by going through the same steps as above and answering the questions in the 
checklist for the client level. Once the barriers have been identified and listed in order of 
priority, possible solutions for overcoming these barriers can be identified.
 | Scenario 2
Description of the situation
In country Y, it is believed that the HCV epidemic is mainly concentrated among people 
who inject drugs, but up-to-date figures are unavailable. Despite the existence of 
a national hepatitis action plan, there are still barriers at the system level that prevent the 
efficient scale-up of HCV testing among people who inject drugs. However, exactly which 
barriers play the most significant roles, and which can be overcome, is unknown. Data on 
HCV prevalence among people who inject drugs are available, and so are data on testing 
uptake, which is low. Some drug services offer HCV testing, but this has not improved 
testing uptake among people who inject drugs. The reasons for this are unknown.
Objectives
Objectives include identifying the main barriers at the system, provider and client levels 
(the five most important at each level) that hinder implementation of HCV testing, but the 
main objective is to identify solutions to overcome these barriers.
Participants
 ■ One representative from the policy level/political scene.
 ■ One representative from a national or regional/local public health 
institute.
 ■ Four representatives from the provider level: two from a drug service that 
implements HCV testing and two from a drug service that does not offer 
HCV testing.
 ■ Four representatives from the client level: two who attend the drug 
service that offers HCV testing and two who do not attend and have not 
been tested for HCV.
Structure of discussion and use of checklist
Since barriers at all levels should be identified, but the main focus is on identifying 
solutions, to save time and ensure constructive discussion, in this case the checklist, 
with some brief instructions, could be shared with the participants before the round-table 
discussion. Participants could be asked to complete the checklist and send it back some 
time before the round-table discussion takes place, to leave enough time to summarise the 
answers and barriers identified at each of the three levels.
After a round of introductions of the participants and the presentation of basic ground 
rules and the objectives of the meeting and the agenda, the discussion could start with 
the facilitator providing a brief summary of the results from the participants’ responses 
to the checklist and presenting the most commonly identified/agreed on barriers. 
These prioritised barriers could then be discussed with the participants, with a focus on 
identifying solutions for overcoming these. While the answers to the checklist received and 
summarised at the start of the meeting will allow discussions to be focused more directly 
on the topic, it is possible that more or other barriers will be identified when discussing the 
results and looking for potential solutions. There should be room for alterations of the initial 
results, as participants getting together at a round-table discussion may stimulate more 
thoughts and ideas than participants completing the checklist by themselves.
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Appendix 2 I Three round-table scenarios
 | Scenario 3
Description of the situation
It is known that the HCV epidemic is mainly concentrated around people who inject drugs, 
and this group represents the majority of new HCV cases in country Z. The country has just 
begun to implement its first 4-year national hepatitis action plan and, according to recent 
data, the uptake of HCV testing among people who inject drugs is high, but the proportion 
of people who inject drugs who access hepatitis C treatment is low. Prior to the round-
table discussion, another stakeholder consultation had been held to discuss access to 
hepatitis C treatment among healthcare practitioners working in drug treatment centres. 
This means that most of the current round-table participants had already discussed 
existing barriers together and are familiar with each other.
The planning of the round table is led by a core coordination team that consists of the 
EMCDDA national focal point and two other experts with technical backgrounds in and 
knowledge of hepatitis C/HIV and people who inject drugs in the country, linked to the 
national infectious diseases department. Members of the team take turns chairing and 
presenting at the round table, depending on content.
While some main barriers to testing and access to HCV treatment and explanations 
for these barriers are known and may have been addressed previously, others are less 
evident. There is a need to gather people from different levels to reach a consensus and 
an understanding regarding the existing barriers and develop possible solutions for these 
barriers at different levels (service provider/practitioner and client levels).
Objectives
1. To have a clearer and common view of the barriers and solutions to HCV testing:
 ■ to achieve common ground (consensus) regarding the main barriers to 
testing at each level;
 ■ to suggest a list of solutions per barrier and organise them into 
a hierarchical order according to their feasibility.
2.  To have a clearer and common view of what a barrier is and what facilitates linkage 
to care:
 ■ to achieve common ground (consensus) regarding the main barriers to 
linkage to care;
 ■ to suggest a list of solutions per barrier and organise them into 
a hierarchical order according to their feasibility.
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Participants
 ■ Prison psychiatrist
 ■ Infectious disease physicians
 ■ Infectious disease nurses
 ■ Directors and healthcare practitioners from drug treatment centres
 ■ Directors and healthcare practitioners from low-threshold centres
 ■ Representatives from the Directorate of Health, including the coordinator 
of the current and future national strategy and action plan against illicit 
drugs and associated addictions
 ■ Coordinator of the national hepatitis action plan
 ■ Deputy head of the National Infectious Diseases Research Unit and 
president of the Surveillance Committee for AIDS, Hepatitis and Sexually 
Transmitted Diseases.
Structure of discussion and use of checklist
Since barriers at all levels should be identified, the checklist could be circulated prior to 
the round-table discussion. Participants could be asked to complete the checklist and 
submit their replies to the coordination team before the meeting, to save time and ensure 
constructive discussion. The barriers identified in the replies to the checklist submitted 
could be presented briefly, as well as barriers identified during the earlier consultation 
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GETTING IN TOUCH WITH THE EU
In person
All over the European Union there are hundreds of Europe Direct 
information centres. You can find the address of the centre nearest 
you at: https://europa.eu/european-union/contact_en
On the phone or by email
Europe Direct is a service that answers your questions about the 
European Union. You can contact this service:
•  by freephone: 00 800 6 7 8 9 10 11  
(certain operators may charge for these calls),
• at the following standard number: +32 22999696, or
• by email via: https://europa.eu/european-union/contact
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the EU is available on the Europa website at: https://europa.eu
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https://publications.europa.eu/en/publications.  
Multiple copies of free publications may be obtained by contacting 
Europe Direct or your local information centre (see  
https://europa.eu/european-union/contact).
About this publication
This manual provides a step-by-step guide for those 
involved in planning and managing infectious diseases 
and drug services, focusing on how to identify barriers 
to and opportunities for improving provision of HCV 
testing and access to treatment for people who use 
drugs. In particular, it focuses on HCV testing in harm 
reduction and drug treatment settings.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For 25 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
